Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

Revenue projections:

Revenue projections for SANOFI
Revenue projections for SANOFI

Revenues for SANOFI are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 1.849000
forwardPE 27.931936
debtToEquity 2.672000
earningsGrowth -0.326000
revenueGrowth -0.123000
grossMargins 0.508400
operatingMargins 0.211170
trailingEps 157.520000
forwardEps 203.770000

Sanofi India Limited's current ratio being 1.849 suggests that the company has no issue servicing its short-term debt. Its strong liquidity position, supported by sufficient cash reserves and current assets, ensures that Sanofi India Limited can meet its financial obligations with ease.
SANOFI's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
SANOFI's low growth in earnings and revenue indicates a potential decline in profits. This suggests that the company could be facing financial challenges, making it harder to sustain its current profit margins.
SANOFI's positive gross and operating margins indicate healthy profitability. These margins reflect the company's ability to generate income efficiently from its operations, signaling strong financial performance and effective cost management.
SANOFI's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting SANOFI to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for SANOFI
Price projections for SANOFI

SANOFI's price projections have gradually declined, indicating growing uncertainty about the company's ability to meet previous targets. The downward trend reflects a more conservative view of SANOFI's future.

Recommendation changes over time:

Recommendations trend for SANOFI
Recommendations trend for SANOFI


Analysts are favoring SANOFI with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider SANOFI as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.